WearLinq announced today that it acquired an independent diagnostic testing facility (IDTF) to increase access to its eWave wearable ECG.
The company acquired AMI Cardiac Monitoring, an IDTF with more than 33 years of expertise in ambulatory cardiac monitoring. It expects the acquisition to fuel its capacity to offer clinical services and the eWave system. eWave, a 6-lead wearable ECG monitor, recently received FDA 510(k) clearance.
Related: Stereotaxis to acquire Access Point Technologies and its EP catheters
San Francisco-based WearLinq’s acquisition also comes on the heels of a $6.7 million early-stage fundraising round. Angel investors from established cardiac monitoring players iRhythm and AliveCor participated in that early investment. Joe Knight, joint inventor of iRhythm’s Zio system, also joined WearLinq’s board of directors.
“The astute clinical capabilities of AMI combined with the advanced technology of WearLinq will create a tremendously productive partnership,” said Konrad Morzkowski, CEO of WearLinq. “AMI and WearLinq share the same values and visions of providing excellent services for patients and clinical facilities. This synergy enhances our ability to deliver comprehensive cardiac diagnostics, promising significant advancements in healthcare services for cardiac patients and will undoubtedly position us as market leaders very soon.”
WearLinq designed its system to provide a detailed, multidimensional view of the heart. It ensures P-wave visibility and ECG clarity. The system works with the patient’s smartphone, allowing for long-term monitoring. It also has convenient recharging in an AirPods-like case and magnetically attaches to the company’s (patent pending) skin-like adhesive patches.
The device also integrates with a state-of-the-art cloud platform for near-real-time data analysis and actionable insights.
Dorothy Glodek, founder of AMI, said the acquisition could help “revolutionize the field of ambulatory cardiac monitoring.”
“This is just the beginning; we have an exciting pipeline of AI products to further empower patients and providers, as well as take our reach beyond cardiac monitoring,” said Morzkowski. “We are dedicated to continuous innovation and expanding our impact across the healthcare spectrum.”
